The Myeloma Beacon » Avastin (bevacizumab, rhuMAb-VEGF)

Avastin (bevacizumab, rhuMAb-VEGF)

By: Admin; Published: October 15, 2008 @ 8:00 am | Comments Disabled

Brand Name:	Avastin
Generic Name:	bevacizumab
Code Name:	rhuMAb-VEGF
Company:	Genentech Inc.
FDA Clinical Phase:	1/2

Description:

Avastin is a monoclonal antibody used in the treatment of colorectal cancer that has spread. It is also being studied in the treatment of other types of cancer. Avastin binds to vascular endothelial growth factor (VEGF) and may stop the growth of new blood vessels needed for tumors to grow. It is a type of antiangiogenesis agent.

Clinical Trials:
For a list of clinical trials studying Avastin for the treatment of multiple myeloma, see ClinicalTrials.gov ^[1].

Official website for Avastin: http://www.avastin.com/ ^[2]

Source: NCI Cancer Glossary, Avastin, http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Avastin ^[3] (as of September 8, 2008)

Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2008/10/15/avastin/

URLs in this post:

[1] ClinicalTrials.gov: http://www.clinicaltrial.gov/ct2/results?cond=multiple+myeloma&intr=Avastin

[2] http://www.avastin.com/: http://www.avastin.com/

[3] http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Avastin: http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Avastin

Click here to print.